Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents
Objective We aimed to investigate the remission rate and disease duration in idiopathic or post–cardiac injury pericarditis and risk factors for disease duration and anti–interleukin‐1 (IL‐1) agent discontinuation. Methods This was a multicenter, longitudinal, observational study including 370 patie...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542351469314048 |
|---|---|
| author | Elisa Ceriani Francesco Agozzino Silvia Berra Antonio Gidaro Paolo Bindi Alberto Pavarani Silvia Macchi Letizia Vena Francesco Moda Ludovico Luca Sicignano Celeste Ambra Murace Laura Gerardino Elena Verrecchia Caterina Chiara De Carlini Silvia Maestroni Gabriella Marinaro Emanuele Bizzi Antonio Brucato Massimo Imazio |
| author_facet | Elisa Ceriani Francesco Agozzino Silvia Berra Antonio Gidaro Paolo Bindi Alberto Pavarani Silvia Macchi Letizia Vena Francesco Moda Ludovico Luca Sicignano Celeste Ambra Murace Laura Gerardino Elena Verrecchia Caterina Chiara De Carlini Silvia Maestroni Gabriella Marinaro Emanuele Bizzi Antonio Brucato Massimo Imazio |
| author_sort | Elisa Ceriani |
| collection | DOAJ |
| description | Objective We aimed to investigate the remission rate and disease duration in idiopathic or post–cardiac injury pericarditis and risk factors for disease duration and anti–interleukin‐1 (IL‐1) agent discontinuation. Methods This was a multicenter, longitudinal, observational study including 370 patients (51.4% female). The remission rate was the proportion of patients who stopped all pericarditis‐related therapies for at least 6 months without recurrences. Results The median follow‐up was 4.9 (interquartile range [IQR] 2.8–8.4) years, and the median age at the end of follow‐up was 49 (IQR 37–60) years. A median of 1.1 (IQR 0.6–1.9) recurrences/year and 0.4 (IQR 0.1–0.9) hospitalizations/year were recorded. The remission rate at follow‐up was 34.0%, 7% per year. Disease duration was shorter for patients in remission (3.1 years, IQR 1.6–6.2 years) than for those still receiving treatment (4 years, IQR 2.2–7.8; P = 0.02). Use of “guidelines‐based therapy” (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.25–2.73; P = 0.02) and colchicine use at first attack (HR 1.51, 95% CI 1.02–2.23; P = 0.038) were protective factors, whereas steroid use was associated with longer disease duration (HR 0.53, 95% CI 0.35–0.81; P = 0.003). Corticosteroids were used in 77.3% of patients, with a median duration of therapy of 1.1 (IQR 0.4–2.6) years. Anakinra was used in 25.9% with a median duration of therapy of 2.4 (IQR 0.9–5.0) years; only 19.8% were able to stop anakinra at the end of observation period. Conclusion This study reports the largest and longest follow‐up in patients with recurrent pericarditis. Guideline adherence from the first attack is associated with a shorter course. The disease was long and impacting in terms of recurrences and hospitalizations, often requiring a long‐term treatment, in particular with anti–IL‐1 agents. |
| format | Article |
| id | doaj-art-0649d29e75da4fbd963aa75ef5a05608 |
| institution | Kabale University |
| issn | 2578-5745 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj-art-0649d29e75da4fbd963aa75ef5a056082025-02-04T06:21:23ZengWileyACR Open Rheumatology2578-57452025-01-0171n/an/a10.1002/acr2.11776Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 AgentsElisa Ceriani0Francesco Agozzino1Silvia Berra2Antonio Gidaro3Paolo Bindi4Alberto Pavarani5Silvia Macchi6Letizia Vena7Francesco Moda8Ludovico Luca Sicignano9Celeste Ambra Murace10Laura Gerardino11Elena Verrecchia12Caterina Chiara De Carlini13Silvia Maestroni14Gabriella Marinaro15Emanuele Bizzi16Antonio Brucato17Massimo Imazio18Ospedale Luigi Sacco Milan ItalyOspedale Fatebenefratelli Milan ItalyOspedale Fatebenefratelli Milan ItalyOspedale Luigi Sacco Milan ItalyUniversity of Milan Milan ItalyUniversity of Milan Milan ItalyUniversity of Milan Milan ItalyUniversity of Milan Milan ItalyUniversity of Milan Milan ItalyUniversità Cattolica del Sacro Cuore and Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS Rome ItalyUniversità Cattolica del Sacro Cuore and Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS Rome ItalyUniversità Cattolica del Sacro Cuore and Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS Rome ItalyUniversità Cattolica del Sacro Cuore and Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS Rome ItalySan Leopoldo Mandic Hospital Merate, Lecco ItalyPapa Giovanni XXIII Hospital Bergamo ItalyOspedale Fatebenefratelli Milan ItalyOspedale Fatebenefratelli Milan ItalyOspedale Fatebenefratelli and University of Milan Milan ItalyUniversity of Udine and University Hospital Santa Maria della Misericordia Udine ItalyObjective We aimed to investigate the remission rate and disease duration in idiopathic or post–cardiac injury pericarditis and risk factors for disease duration and anti–interleukin‐1 (IL‐1) agent discontinuation. Methods This was a multicenter, longitudinal, observational study including 370 patients (51.4% female). The remission rate was the proportion of patients who stopped all pericarditis‐related therapies for at least 6 months without recurrences. Results The median follow‐up was 4.9 (interquartile range [IQR] 2.8–8.4) years, and the median age at the end of follow‐up was 49 (IQR 37–60) years. A median of 1.1 (IQR 0.6–1.9) recurrences/year and 0.4 (IQR 0.1–0.9) hospitalizations/year were recorded. The remission rate at follow‐up was 34.0%, 7% per year. Disease duration was shorter for patients in remission (3.1 years, IQR 1.6–6.2 years) than for those still receiving treatment (4 years, IQR 2.2–7.8; P = 0.02). Use of “guidelines‐based therapy” (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.25–2.73; P = 0.02) and colchicine use at first attack (HR 1.51, 95% CI 1.02–2.23; P = 0.038) were protective factors, whereas steroid use was associated with longer disease duration (HR 0.53, 95% CI 0.35–0.81; P = 0.003). Corticosteroids were used in 77.3% of patients, with a median duration of therapy of 1.1 (IQR 0.4–2.6) years. Anakinra was used in 25.9% with a median duration of therapy of 2.4 (IQR 0.9–5.0) years; only 19.8% were able to stop anakinra at the end of observation period. Conclusion This study reports the largest and longest follow‐up in patients with recurrent pericarditis. Guideline adherence from the first attack is associated with a shorter course. The disease was long and impacting in terms of recurrences and hospitalizations, often requiring a long‐term treatment, in particular with anti–IL‐1 agents.https://doi.org/10.1002/acr2.11776 |
| spellingShingle | Elisa Ceriani Francesco Agozzino Silvia Berra Antonio Gidaro Paolo Bindi Alberto Pavarani Silvia Macchi Letizia Vena Francesco Moda Ludovico Luca Sicignano Celeste Ambra Murace Laura Gerardino Elena Verrecchia Caterina Chiara De Carlini Silvia Maestroni Gabriella Marinaro Emanuele Bizzi Antonio Brucato Massimo Imazio Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents ACR Open Rheumatology |
| title | Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents |
| title_full | Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents |
| title_fullStr | Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents |
| title_full_unstemmed | Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents |
| title_short | Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents |
| title_sort | duration of disease and long term outcomes in patients with difficult to treat recurrent pericarditis a chronic condition treated with nonsteroidal anti inflammatory drugs colchicine corticosteroids and anti interleukin 1 agents |
| url | https://doi.org/10.1002/acr2.11776 |
| work_keys_str_mv | AT elisaceriani durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT francescoagozzino durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT silviaberra durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT antoniogidaro durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT paolobindi durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT albertopavarani durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT silviamacchi durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT letiziavena durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT francescomoda durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT ludovicolucasicignano durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT celesteambramurace durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT lauragerardino durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT elenaverrecchia durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT caterinachiaradecarlini durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT silviamaestroni durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT gabriellamarinaro durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT emanuelebizzi durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT antoniobrucato durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents AT massimoimazio durationofdiseaseandlongtermoutcomesinpatientswithdifficulttotreatrecurrentpericarditisachronicconditiontreatedwithnonsteroidalantiinflammatorydrugscolchicinecorticosteroidsandantiinterleukin1agents |